Search hospitals > Ohio > Toledo

University of Toledo

Claim this profile
Toledo, Ohio 43614
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
207 reported clinical trials
8 medical researchers
Photo of University of Toledo in ToledoPhoto of University of Toledo in ToledoPhoto of University of Toledo in Toledo

Summary

University of Toledo is a medical facility located in Toledo, Ohio. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Breast cancer and other specialties. University of Toledo is involved with conducting 207 clinical trials across 353 conditions. There are 8 research doctors associated with this hospital, such as Roland Skeel, MD, Mouhammad Jumaa, MD, Firas G. Petros, and Ahmad Zarzour.

Area of expertise

1Lung Cancer
Global Leader
University of Toledo has run 30 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I
2Breast Cancer
Global Leader
University of Toledo has run 24 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
PR positive

Top PIs

Clinical Trials running at University of Toledo

Lung Cancer
Bladder Cancer
Prostate Cancer
Kidney Cancer
Pancreatic Cancer
Cancer
ALK Gene Rearrangement
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

TTX-080 +/− Cetuximab/Pembrolizumab

for Cancer

This trial tests TTX-080, a new drug, alone and with other cancer drugs in patients with hard-to-treat cancers. It works by helping the immune system find and attack cancer cells.
Recruiting1 award Phase 14 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Toledo?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security